VTGN Earnings Prediction
The chart below shows how VTGN performed 10 days before and after its earnings report, based on data from the past quarters. Typically, VTGN sees a -4.01% change in stock price 10 days leading up to the earnings, and a -2.42% change 10 days following the report. On the earnings day itself, the stock moves by -0.25%. This data can give you a slight idea of what to expect for the next quarter's release.
VTGN Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
183.00K
-34.10%
117.86%
Gross Margin
--
--
--
Operating Margin
-7774.32%
218.42%
-46.17%
Net Margin
-7082.51%
198.56%
-44.57%
EPS
-0.42
-36.36%
20.00%
No Data Available
VTGN Earnings Analysis
Vistagen Therapeutics, Inc. Common Stock Corporation (VTGN.O) Earnings Conference Call
Positive
R&D Expense Increase: Research and development expenses were $10.2 million for the quarter ended September 30, 2024, compared to $3.9 million for the same period last year, indicating a significant increase in investment in R&D.
R&D Expense Increase: The increase in R&D expenses was primarily due to an increase in clinical and development expenses related to our PALISADE Phase 3 program for fasedenol for the acute treatment of SAD.
Administrative Expense Increase: General and administrative expenses were $4.2 million for the quarter ended September 30, 2024, compared to $3.2 million for the same period last year, reflecting growth in operational support.
Strong Financial Position: As of September 30, 2024, we had $97.6 million in cash, cash equivalents, and marketable securities, providing a strong financial position to support ongoing projects.
Innovation in Pharmaceutical Care: We are advancing multiple opportunities to set new standards of care in several high-prevalence pharmaceutical markets, demonstrating our commitment to innovation and growth.
Negative
R&D Expense Increase: Research and development expenses were $10.2 million for the quarter ended September 30, 2024, compared to $3.9 million for the same period last year.
R&D Expense Increase: The increase in R&D expenses was primarily due to an increase in clinical and development expenses related to our PALISADE Phase 3 program for fasedenol for the acute treatment of SAD, an increase in headcount and an increase in consulting and professional services.
Administrative Expense Increase: General and administrative expenses were $4.2 million for the quarter ended September 30, 2024, compared to $3.2 million for the same period last year.
G&A Expense Increase: The increase in G&A expenses was primarily due to an increase in headcount and professional services fees.
Net Loss Comparison: Our net loss attributable to common stockholders was $13 million for the quarter ended September 30, 2024, compared to $6.6 million for the same period last year.
VTGN FAQs
How does VTGN typically perform around its earnings report dates?
Is Vistagen Therapeutics, Inc. (VTGN) Q2 2025 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
VTGN Earning Call Sentiment
Vistagen Therapeutics, Inc. (VTGN) Q2 2025 Earnings Call Transcript
1.0x
00:00
00:00
VTGN.O
3.5%Positive
The earnings call highlights significant financial strain with a 97% increase in net loss and a 161% rise in R&D expenses. Despite a strong cash position, the company faces regulatory, operational, and competitive risks. The Q&A reveals uncertainty in project timelines and management's unclear responses. These factors, combined with increased expenses and market competition, suggest a negative sentiment towards the stock's short-term performance.